Guardant Health (NASDAQ: GH) HR chief reports stock sales in Form 4 filing

Q: What did Guardant Health (GH) disclose in this Form 4 filing?

The filing shows that Chief People Officer Terilyn J. Monroe sold Guardant Health common stock in three separate transactions on January 7, 2026 , and reports her updated shareholdings.

Q: How many Guardant Health shares did Terilyn J. Monroe sell?

She sold 6,311 shares at $111.7521 per share, 3,632 shares at $112.6182 per share, and 88 shares at $113.4397 per share of Guardant Health common stock.

Q: Who is the insider involved in this Guardant Health Form 4?

The reporting person is Terilyn J. Monroe , who serves as Chief People Officer of Guardant Health and is identified as an officer but not a director or 10% owner.

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Guardant Health’s Chief People Officer, Terilyn J. Monroe, reported selling common stock in three transactions on January 7, 2026. She sold 6,311 shares at a weighted average price of $111.7521 per share, 3,632 shares at $112.6182 per share, and 88 shares at $113.4397 per share. After these sales, she held 20,990 shares of Guardant Health common stock directly. The prices reported are weighted averages for multiple trades within disclosed price ranges.

Insider Trade Summary

Net Seller: 10,031 shares ($1,124,279)

Net Sell 3 txns

Insider Monroe Terilyn J.

Role Chief People Officer

Sold 10,031 shs ($1.12M)

Type	Security	Shares	Price	Value
Sale	Common Stock	6,311	$111.7521	$705K
Sale	Common Stock	3,632	$112.6182	$409K
Sale	Common Stock	88	$113.4397	$10K

Holdings After Transaction: Common Stock — 24,710 shares (Direct)

Footnotes (1)

Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $111.230 to $112.175. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $112.260 to $113.250. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $113.410 to $113.490. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

Form 4 Insider Transactions: What Each Field Means →

01/09/2026 - 04:09 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Monroe Terilyn J.

(Last)

(First)

(Middle)

3100 HANOVER STREET

(Street)

PALO ALTO

94304

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief People Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/07/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/07/2026		S		6,311	D	$111.7521⁽¹⁾	24,710	D
Common Stock	01/07/2026		S		3,632	D	$112.6182⁽²⁾	21,078	D
Common Stock	01/07/2026		S		88	D	$113.4397⁽³⁾	20,990	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $111.230 to $112.175. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

2. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $112.260 to $113.250. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

3. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $113.410 to $113.490. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

Remarks:

	/s/ John G. Saia, as attorney-in-fact for Tarilyn J. Monroe	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did Guardant Health (GH) disclose in this Form 4 filing?

The filing shows that Chief People Officer Terilyn J. Monroe sold Guardant Health common stock in three separate transactions on January 7, 2026, and reports her updated shareholdings.

How many Guardant Health shares did Terilyn J. Monroe sell?

She sold 6,311 shares at $111.7521 per share, 3,632 shares at $112.6182 per share, and 88 shares at $113.4397 per share of Guardant Health common stock.

How many Guardant Health (GH) shares does the insider own after these sales?

Following the reported transactions, Terilyn J. Monroe beneficially owns 20,990 shares of Guardant Health common stock in direct ownership.

Who is the insider involved in this Guardant Health Form 4?

The reporting person is Terilyn J. Monroe, who serves as Chief People Officer of Guardant Health and is identified as an officer but not a director or 10% owner.

What price ranges were involved in the Guardant Health stock sales?

The sales were reported as weighted average prices, with underlying trade prices ranging from $111.230 to $112.175, from $112.260 to $113.250, and from $113.410 to $113.490, respectively.

Are the Guardant Health insider transactions direct or indirect holdings?

The Form 4 shows that the reported holdings after the transactions, totaling 20,990 shares, are held in direct ownership by Terilyn J. Monroe.